




Phenacetin-rat-HTPBTK-OPERA, RMSLE=0.582 10² -10 factor(Dose) 10 Concentration (mg/L) 23 250 360 factor(Route) · oral 10⁻¹ -10⁻² -0.25 0.50 0.75 0.00 1.00 Time_Days (h)




Phenacetin-rat-HTPBTK-Consensus, RMSLE=0.435 10² -10 factor(Dose) 10 Concentration (mg/L) 23 250 360 factor(Route) iv · oral 10⁻¹ -10⁻² -0.25 0.50 0.75 0.00 1.00 Time_Days (h)





Phenacetin-rat-In Vivo Fits, RMSLE=0.446 10² -10 factor(Dose) 10 Concentration (mg/L) 23 250 360 factor(Route) oral 10⁻¹ -10⁻² -0.25 0.50 0.00 0.75 1.00 Time_Days (h)







Dichloromethane-rat-HTPBTK-OPERA, RMSLE=0.475 10² -30 -Concentration (mg/L) factor(Route) - oral factor(Dose) 10 -125 3 -0.05 0.10 0.15 0.00 0.20 Time_Days (h)













Trichloroethylene-rat-HTPBTK-InVitro, RMSLE=0.743 10 factor(Route) Concentration (mg/L) oral factor(Dose) 7.6 18 10⁻¹ -0.00 0.05 0.10 0.15 Time_Days (h)


Trichloroethylene-rat-HTPBTK-OPERA, RMSLE=0.807 10 factor(Route) Concentration (mg/L) oral factor(Dose) 7.6 18 10⁻¹ -0.05 0.00 0.10 0.15 Time_Days (h)




















































Tetrachloroethylene-rat-HTPBTK-InVitro, RMSLE=0.381 10² -Concentration (mg/L) factor(Route) 10 -- oral factor(Dose) 500 1 -0.0 0.5 1.0 1.5 Time_Days (h)


Tetrachloroethylene-rat-HTPBTK-OPERA, RMSLE=0.381 10² -Concentration (mg/L) factor(Route) 10 -- oral factor(Dose) 500 1 -0.0 0.5 1.0 1.5 Time_Days (h)


Tetrachloroethylene-rat-HTPBTK-Consensus, RMSLE=0.381 10² -Concentration (mg/L) factor(Route) 10 -- oral factor(Dose) 500 1 -0.0 0.5 1.0 1.5 Time_Days (h)





Acrylonitrile-rat-HTPBTK-Consensus, RMSLE=0.323 10² factor(Dose) Concentration (mg/L) 3.4 10 -47 55 84 factor(Route) 1 -10⁻¹ - 0.00 0.01 0.02 0.03 0.04 0.05 Time_Days (h)






Methyl tert-butyl ether-human-HTPBTK-OPERA, RMSLE=0.832 10⁻¹ factor(Route) Concentration (mg/L) oral 10⁻² factor(Dose) 0.0671 0.199 10⁻³ -0.1 0.2 0.5 0.3 0.4 Time_Days (h)

Methyl tert-butyl ether-human-HTPBTK-Consensus, RMSLE=0.318 0.03 factor(Route) Concentration (mg/L) 10⁻² oral factor(Dose) 0.0671 0.199 0.003 -10⁻³ -0.1 0.2 0.3 0.4 0.5 Time_Days (h)


tert-Amyl methyl ether-human-HTPBTK-InVitro, RMSLE=0.297 0.03 -10⁻² factor(Route) Concentration (mg/L) oral 0.003 factor(Dose) 0.0671 0.201 10⁻³ -3e-04 **-**0.1 0.2 0.3 0.4 0.5 Time_Days (h)


tert-Amyl methyl ether-human-HTPBTK-OPERA, RMSLE=0.928 0.03 -10⁻² factor(Route) Concentration (mg/L) oral factor(Dose) 0.0671 0.003 -0.201 10⁻³ -3e-04 -0.2 0.1 0.5 0.3 0.4 Time_Days (h)


tert-Amyl methyl ether-human-HTPBTK-Consensus, RMSLE=0.832 10⁻² factor(Route) Concentration (mg/L) 0.003 oral factor(Dose) 0.0671 0.201 10⁻³ -3e-04 **-**0.1 0.2 0.5 0.3 0.4 Time_Days (h)



Propylparaben-rat-HTPBTK-ADmet, RMSLE=0.53 10² -10 factor(Route) Concentration (mg/L) oral factor(Dose) 3 1 -10 100 1000 10⁻¹ -0.05 0.10 0.00 0.15 Time_Days (h)








Propylparaben-rat-HTPBTK-Consensus, RMSLE=0.463 10² -10 factor(Route) Concentration (mg/L) oral factor(Dose) 3 1 -10 100 1000 10⁻¹ 0.05 0.10 0.00 0.15 Time_Days (h)

2,4-Dichlorophenoxyacetic acid-rat-HTPBTK-InVitro, RMSLE=0.762 10 factor(Dose) 0.205 1.04 Concentration (mg/L) 1.5 2 3.56 factor(Route) oral 10⁻³ -0.25 0.50 0.75 0.00 1.00 Time_Days (h)





2,4-Dichlorophenoxyacetic acid-rat-HTPBTK-Dawson, RMSLE=0.736 10 factor(Dose) 0.205 1.04 Concentration (mg/L) 1.5 2 3.56 factor(Route) oral 10⁻³ -0.25 0.50 0.75 0.00 1.00 Time_Days (h)


2,4-Dichlorophenoxyacetic acid-rat-HTPBTK-Pradeep, RMSLE=0.628 10 factor(Dose) 0.205 1.04 Concentration (mg/L) 1.5 2 3.56 factor(Route) oral 10⁻³ -0.25 0.50 0.75 0.00 1.00 Time_Days (h)


2,4-Dichlorophenoxyacetic acid-rat-HTPBTK-OPERA, RMSLE=0.762 10 factor(Dose) 0.205 1.04 Concentration (mg/L) 1.5 2 3.56 factor(Route) oral 10⁻³ -0.25 0.50 0.75 0.00 1.00 Time_Days (h)


 $2,4-Dichlorophenoxyacetic\ acid-rat-HTPBTK-Consensus,\ RMSLE=1.45$ 10 factor(Dose) 0.205 1.04 Concentration (mg/L) 1.5 2 3.56 factor(Route) oral 10⁻³ -0.25 0.50 0.75 0.00 1.00 Time_Days (h)



























Alprazolam-rat-HTPBTK-ADmet, RMSLE=1.8 10 -1 factor(Dose) Concentration (mg/L) 1.25 12.5 factor(Route) · oral 10⁻² -10⁻³ -0.05 0.10 0.15 0.20 0.25 0.00 Time_Days (h)








Alprazolam-rat-HTPBTK-OPERA, RMSLE=1.82 10 -1 factor(Dose) Concentration (mg/L) 1.25 7 12.5 10⁻¹ factor(Route) · oral 10⁻² -10⁻³ -0.05 0.10 0.15 0.20 0.25 0.00 Time_Days (h)






















Phenazone-rat-HTPBTK-Consensus, RMSLE=0.371 10 -5 -Concentration (mg/L) factor(Dose) 15 factor(Route) iv 0.10 0.15 0.05 Time_Days (h)








































































































1-Naphthalenol, 1-(N-methylcarbamate)-rat-In Vivo Fits, RMSLE=0.643 0.03 -10⁻² factor(Dose) Concentration (mg/L) factor(Route) 0.003 iv · oral 10⁻³ -0.01 0.02 0.03 0.04 Time_Days (h)


Carbendazim-rat-HTPBTK-InVitro, RMSLE=1.08 10² -10 -Concentration (mg/L) factor(Route) oral factor(Dose) 1000 1 -10⁻¹ -0.0 0.2 0.4 0.6 0.8 Time_Days (h)











Carbendazim-rat-HTPBTK-OPERA, RMSLE=1.08 10² -10-Concentration (mg/L) factor(Route) **▶** oral factor(Dose) 1000 1 -10⁻¹ -0.0 0.2 0.4 0.6 0.8 Time_Days (h)







































































































Fenarimol-rat-HTPBTK-Dawson, RMSLE=1.29 1 factor(Dose) Concentration (mg/L) 0.4 2 factor(Route) iv oral 10⁻² -0.1 0.2 0.4 0.0 0.3 0.5 Time_Days (h)





































Formetanate hydrochloride-rat-HTPBTK-Dawson, RMSLE=0.968 1 -10⁻¹ factor(Dose) Concentration (mg/L) factor(Route) iv · oral 10⁻² -2 3 Time_Days (h)




Formetanate hydrochloride-rat-HTPBTK-OPERA, RMSLE=0.872 0.3 -10⁻¹ factor(Dose) Concentration (mg/L) 0.03 factor(Route) iv · oral 10⁻² -0.003 -2 0 3 Time_Days (h)

Formetanate hydrochloride-rat-HTPBTK-Consensus, RMSLE=0.664 0.3 -10⁻¹ factor(Dose) Concentration (mg/L) 0.03 factor(Route) 10⁻² -· oral 0.003 -2 3 0 Time_Days (h)



Ibuprofen-rat-HTPBTK-InVitro, RMSLE=0.788 10² -10 -Concentration (mg/L) factor(Dose) 2.5 25 factor(Route) 10⁻¹ -0.0 0.2 0.6 0.4 Time_Days (h)

Ibuprofen-rat-HTPBTK-ADmet, RMSLE=0.791 10² -10 factor(Dose) Concentration (mg/L) 2.5 25 factor(Route) 10⁻¹ -0.0 0.2 0.6 0.4 Time_Days (h)





Ibuprofen-rat-HTPBTK-Pradeep, RMSLE=0.794 10² -10 factor(Dose) Concentration (mg/L) 2.5 25 factor(Route) 10⁻¹ -0.0 0.2 0.6 0.4 Time_Days (h)


Ibuprofen-rat-HTPBTK-OPERA, RMSLE=0.692 10² -10 -Concentration (mg/L) factor(Dose) 2.5 25 factor(Route) 10⁻¹ -0.0 0.2 0.6 0.4 Time_Days (h)


Ibuprofen-rat-HTPBTK-Consensus, RMSLE=0.359 10² -10 factor(Dose) Concentration (mg/L) 2.5 25 factor(Route) 10⁻¹ -0.0 0.2 0.6 0.4 Time_Days (h)


Ibuprofen-rat-In Vivo Fits, RMSLE=0.184 10² -10 factor(Dose) Concentration (mg/L) 2.5 25 factor(Route) 10⁻¹ -0.0 0.2 0.6 0.4 Time_Days (h)










































Imipramine-rat-HTPBTK-InVitro, RMSLE=1.54 10 factor(Dose) Concentration (mg/L) 10 50 factor(Route) iv · oral 10⁻¹ -0.25 0.50 0.75 0.00 1.00 Time_Days (h)













Imipramine-rat-HTPBTK-Consensus, RMSLE=1.02 3 -1 factor(Dose) Concentration (mg/L) 10 50 0.3 factor(Route) iv · oral 10⁻¹ -0.03 -0.50 0.25 0.75 0.00 1.00 Time_Days (h)











Midazolam-rat-HTPBTK-OPERA, RMSLE=1.7 10 factor(Dose) Concentration (mg/L) 5 15 10⁻¹ factor(Route) iv · oral 10⁻² -10⁻³ -0.05 0.10 0.15 0.00 Time_Days (h)

















Nilvadipine-rat-HTPBTK-OPERA, RMSLE=2 10 -1 factor(Dose) Concentration (mg/L) 0.1 10 factor(Route) iv · oral 10⁻² -10⁻³ -0.0 0.1 0.2 0.3 0.4 Time_Days (h)










Ondansetron-rat-HTPBTK-ADmet, RMSLE=1.08 10² -10 factor(Route) Concentration (mg/L) · oral factor(Dose) 20 10⁻¹ -0.10 0.05 0.00 0.15 Time_Days (h)


Ondansetron-rat-HTPBTK-Dawson, RMSLE=1.06 10² -10 factor(Route) Concentration (mg/L) · oral factor(Dose) 20 10⁻¹ -0.05 0.10 0.00 0.15 Time_Days (h)







Ondansetron-rat-HTPBTK-Consensus, RMSLE=1.05 10² -10 factor(Route) Concentration (mg/L) · oral factor(Dose) 20 10⁻¹ -0.10 0.05 0.00 0.15 Time_Days (h)





Permethrin-rat-HTPBTK-ADmet, RMSLE=1.58 1 -10⁻¹ factor(Dose) Concentration (mg/L) factor(Route) iv · oral 0.5 0.0 1.0 1.5 2.0 Time_Days (h)







Permethrin-rat-In Vivo Fits, RMSLE=0.402 10⁻¹ -0.03 factor(Dose) Concentration (mg/L) 10⁻² factor(Route) iv · oral 0.003 -0.0 0.5 2.0 1.0 1.5 Time_Days (h)


5,5-Diphenylhydantoin-rat-HTPBTK-InVitro, RMSLE=0.738 10² factor(Dose) Concentration (mg/L) 25 40 factor(Route) 10 iv · oral 1 -0.2 0.0 0.1 0.4 0.5 0.3 Time_Days (h)


5,5-Diphenylhydantoin-rat-HTPBTK-ADmet, RMSLE=0.84 10² factor(Dose) Concentration (mg/L) 25 40 factor(Route) 10 iv · oral 1 -0.2 0.0 0.1 0.4 0.5 0.3 Time_Days (h)





5,5-Diphenylhydantoin-rat-HTPBTK-OPERA, RMSLE=0.757 10² factor(Dose) Concentration (mg/L) 25 40 factor(Route) 10 iv · oral 1 -0.2 0.0 0.1 0.4 0.5 0.3 Time_Days (h)





Propamocarb hydrochloride-rat-HTPBTK-InVitro, RMSLE=2.17 1 -10⁻¹ factor(Dose) Concentration (mg/L) 10⁻² factor(Route) iv · oral 10⁻³ -10⁻⁴ -0.02 0.04 0.00 0.06 0.08 Time_Days (h)


Propamocarb hydrochloride-rat-HTPBTK-ADmet, RMSLE=2.02 10⁻¹ factor(Dose) Concentration (mg/L) 10⁻² factor(Route) iv · oral 10⁻³ -10⁻⁴ -0.02 0.04 0.00 0.06 0.08 Time_Days (h)


Propamocarb hydrochloride-rat-HTPBTK-Dawson, RMSLE=2.3 1 -10⁻¹ factor(Dose) Concentration (mg/L) 10⁻² factor(Route) iv · oral 10⁻³ -10⁻⁴ -0.02 0.04 0.00 0.06 0.08 Time_Days (h)


Propamocarb hydrochloride-rat-HTPBTK-Pradeep, RMSLE=2.16 1 -10⁻¹ factor(Dose) Concentration (mg/L) 10⁻² factor(Route) iv · oral 10⁻³ -10⁻⁴ -0.02 0.04 0.00 0.06 0.08 Time_Days (h)


Propamocarb hydrochloride-rat-HTPBTK-OPERA, RMSLE=2.17 1 -10⁻¹ factor(Dose) Concentration (mg/L) 10⁻² factor(Route) iv · oral 10⁻³ -10⁻⁴ -0.02 0.04 0.00 0.06 0.08 Time_Days (h)


Propamocarb hydrochloride-rat-HTPBTK-Consensus, RMSLE=2 10⁻¹ factor(Dose) Concentration (mg/L) factor(Route) iv · oral 10⁻³ -10⁻⁴ -0.02 0.04 0.06 0.08 0.00 Time_Days (h)




















































































Tolbutamide-rat-HTPBTK-InVitro, RMSLE=0.243 50 factor(Dose) Concentration (mg/L) 10 20 factor(Route) iv · oral 20 -0.0 0.2 0.1 0.3 0.4 0.5 Time_Days (h)











Tolbutamide-rat-HTPBTK-OPERA, RMSLE=0.243 50 factor(Dose) Concentration (mg/L) 10 20 factor(Route) iv · oral 20 -0.0 0.2 0.1 0.3 0.4 0.5 Time_Days (h)





















Valproic acid-rat-HTPBTK-InVitro, RMSLE=0.61 10³ -10² factor(Dose) 10 Concentration (mg/L) 50 100 200 600 10 factor(Route) · oral 1 -0.05 0.10 0.00 0.15 Time_Days (h)


Valproic acid-rat-HTPBTK-ADmet, RMSLE=0.645 10³ -10² factor(Dose) 10 Concentration (mg/L) 50 100 200 600 10 factor(Route) · oral 1 -0.05 0.10 0.00 0.15 Time_Days (h)


Valproic acid-rat-HTPBTK-Dawson, RMSLE=0.615 10³ -10² factor(Dose) 10 Concentration (mg/L) 50 100 200 600 10 factor(Route) oral 1 -0.05 0.10 0.00 0.15 Time_Days (h)





Valproic acid-rat-HTPBTK-OPERA, RMSLE=0.669 10³ -10² factor(Dose) 10 Concentration (mg/L) 50 100 200 600 10 factor(Route) · oral 1 -0.05 0.10 0.00 0.15 Time_Days (h)


Valproic acid-rat-HTPBTK-Consensus, RMSLE=1.48 10³ -10² factor(Dose) 10 Concentration (mg/L) 50 100 200 600 10 factor(Route) · oral 1 -0.05 0.10 0.15 0.00 Time_Days (h)
























Pentachlorophenol-rat-HTPBTK-InVitro, RMSLE=0.739 10² factor(Dose) 5 9.5 Concentration (mg/L) 18.8 38 75 150 10 factor(Route) oral 1 -0.5 0.0 1.5 1.0 Time_Days (h)







Pentachlorophenol-rat-HTPBTK-OPERA, RMSLE=0.739 10² factor(Dose) 5 9.5 Concentration (mg/L) 18.8 38 75 150 10 factor(Route) oral 1 -0.5 0.0 1.5 1.0 Time_Days (h)






Gemfibrozil-rat-HTPBTK-InVitro, RMSLE=0.942 10² -10 factor(Dose) Concentration (mg/L) 4.29 50 100 factor(Route) 1 -· oral 10⁻¹ -0.25 0.50 0.00 0.75 1.00 Time_Days (h)









Gemfibrozil-rat-HTPBTK-OPERA, RMSLE=0.942 10² -10 factor(Dose) Concentration (mg/L) 4.29 50 100 factor(Route) 1 -· oral 10⁻¹ -0.25 0.50 0.00 0.75 1.00 Time_Days (h)


Gemfibrozil-rat-HTPBTK-Consensus, RMSLE=0.987 10² -10 factor(Dose) Concentration (mg/L) 4.29 50 100 factor(Route) 1 -· oral 10⁻¹ -0.00 0.25 0.50 0.75 1.00 Time_Days (h)

Gemfibrozil-rat-In Vivo Fits, RMSLE=0.976 10² -10 factor(Dose) Concentration (mg/L) 4.29 50 100 factor(Route) 1 -· oral 10⁻¹ -0.00 0.25 0.50 0.75 1.00 Time_Days (h)





Dibutyl 1,2-benzenedicarboxylate-rat-HTPBTK-ADmet, RMSLE=0.474 10-Concentration (mg/L) factor(Dose) 20 factor(Route) iv iv 1 -0.006 0.009 0.012 0.003 Time_Days (h)








Dibutyl 1,2-benzenedicarboxylate-rat-HTPBTK-Consensus, RMSLE=0.461 10-Concentration (mg/L) factor(Dose) 20 factor(Route) ⊢ iv 1 -0.006 0.009 0.012 0.003 Time_Days (h)






















Benzophenone-rat-HTPBTK-OPERA, RMSLE=0.889 1 factor(Dose) Concentration (mg/L) 2.5 10 factor(Route) 10⁻¹ -· oral 10⁻² -0.25 0.50 0.75 0.00 1.00 Time_Days (h)

Benzophenone-rat-HTPBTK-Consensus, RMSLE=0.733 1 factor(Dose) Concentration (mg/L) 2.5 10 factor(Route) oral 10⁻² -0.25 0.50 0.75 0.00 1.00 Time_Days (h)




2-Hydroxy-4-methoxybenzophenone-rat-HTPBTK-InVitro, RMSLE=2.78 10² factor(Dose) 8 Concentration (mg/L) 100 250 500 factor(Route) oral 10⁻² -0.2 0.0 0.4 0.6 Time_Days (h)

2-Hydroxy-4-methoxybenzophenone-rat-HTPBTK-ADmet, RMSLE=2.3



2-Hydroxy-4-methoxybenzophenone-rat-HTPBTK-Dawson, RMSLE=2.57 10² factor(Dose) 8




2-Hydroxy-4-methoxybenzophenone-rat-HTPBTK-Pradeep, RMSLE=2.69 10² factor(Dose) 8 Concentration (mg/L) 100 250 500 factor(Route) oral 10⁻² -0.2 0.0 0.4 0.6


Time_Days (h)


2-Hydroxy-4-methoxybenzophenone-rat-HTPBTK-OPERA, RMSLE=2.77 10² factor(Dose) 8 Concentration (mg/L) 100 250 500 factor(Route) oral 10⁻² -0.2 0.0 0.6 0.4 Time_Days (h)


2-Hydroxy-4-methoxybenzophenone-rat-HTPBTK-Consensus, RMSLE=2.08





2-Hydroxy-4-methoxybenzophenone-rat-In Vivo Fits, RMSLE=1.61 10 -1 factor(Dose) 8 Concentration (mg/L) 100 250 500 10⁻¹ factor(Route) · oral 10⁻² -10⁻³ -0.2 0.4 0.0 0.6 Time_Days (h)



































































Etoxazole-rat-HTPBTK-Consensus, RMSLE=1.92 10⁻¹ factor(Dose) Concentration (mg/L) 0.4 2 10⁻² factor(Route) iv · oral 10⁻³ -10⁻⁴ 2 0 Time_Days (h)
















Novaluron-rat-In Vivo Fits, RMSLE=0.376 0.3 -10⁻¹ factor(Dose) Concentration (mg/L) 0.4 2 0.03 factor(Route) iv oral 10⁻² -0.003 -2 Ó 3 Time_Days (h)


































 $2-Methylimidazole-rat-HTPBTK-Pradeep,\ RMSLE=1.33$ 10 -Concentration (mg/L) factor(Dose) 10 factor(Route) ⊢ iv 10⁻¹ -5 10 15 20 Time_Days (h)


2-Methylimidazole-rat-HTPBTK-OPERA, RMSLE=0.988 10 -Concentration (mg/L) factor(Dose) 10 factor(Route) ⊢ iv 10⁻¹ -5 10 15 20 Time_Days (h)


 $2-Methylimidazole-rat-HTPBTK-Consensus,\ RMSLE=1.34$ 10 -Concentration (mg/L) factor(Dose) 10 factor(Route) ⊢ iv 10⁻¹ -5 10 15 20 Time_Days (h)


2-Methylimidazole-rat-In Vivo Fits, RMSLE=0.121 10 -Concentration (mg/L) factor(Dose) 10 factor(Route) 10⁻¹ -5 10 15 20 Time_Days (h)















Dichloroacetic acid-rat-HTPBTK-ADmet, RMSLE=0.744 10² factor(Route) 10-Concentration (mg/L) · oral factor(Dose) 10 40 60 100 1 -10⁻¹ 0.0 0.1 0.2 0.3 Time_Days (h)



Dichloroacetic acid-rat-HTPBTK-Consensus, RMSLE=1.12 10 factor(Route) Concentration (mg/L) · oral factor(Dose) 10 40 60 1 -100 10⁻¹ -0.1 0.2 0.3 0.0 Time_Days (h)

Dichloroacetic acid-rat-In Vivo Fits, RMSLE=0.595 30 -10factor(Route) Concentration (mg/L) · oral 3 factor(Dose) 10 40 60 1 -100 0.3 -0.0 0.1 0.2 0.3 Time_Days (h)

Dibromoacetic acid-rat-HTPBTK-ADmet, RMSLE=0.802 10² factor(Dose) 10 10-25 Concentration (mg/L) 40 50 100 110 125 factor(Route) 1 oral 10⁻¹ -0.0 0.1 0.2 0.3 Time_Days (h)

Dibromoacetic acid-rat-HTPBTK-Pradeep, RMSLE=0.56 10² factor(Dose) 10 10-25 Concentration (mg/L) 40 50 100 110 125 factor(Route) 1 oral 10⁻¹ -0.0 0.1 0.2 0.3 Time_Days (h)

Dibromoacetic acid-rat-HTPBTK-Consensus, RMSLE=0.526 10² factor(Dose) 10 10 -25 Concentration (mg/L) 40 50 100 110 125 factor(Route) 1 oral 10⁻¹ -0.1 0.2 0.0 0.3 Time_Days (h)

Dibromoacetic acid-rat-In Vivo Fits, RMSLE=0.456 10² factor(Dose) 10 10 -25 Concentration (mg/L) 40 50 100 110 125 factor(Route) 1 oral 10⁻¹ -0.0 0.1 0.2 0.3 Time_Days (h)


Bromochloroacetic acid-rat-HTPBTK-ADmet, RMSLE=1.01 10² -10 factor(Dose) 10 Concentration (mg/L) 40 80 100 factor(Route) 1 oral 10⁻¹ -0.1 0.0 0.2 0.3 Time_Days (h)


Bromochloroacetic acid-rat-HTPBTK-Pradeep, RMSLE=0.645 10 factor(Dose) 10 Concentration (mg/L) 40 80 100 factor(Route) oral 10⁻¹ -0.1 0.0 0.2 0.3 Time_Days (h)

Bromochloroacetic acid-rat-HTPBTK-Consensus, RMSLE=0.898 10 factor(Dose) 10 Concentration (mg/L) 40 80 100 factor(Route) oral 10⁻¹ -0.1 0.0 0.2 0.3 Time_Days (h)


Bromochloroacetic acid-rat-In Vivo Fits, RMSLE=0.574 10 factor(Dose) 10 Concentration (mg/L) 40 80 100 factor(Route) oral 10⁻¹ -0.1 0.0 0.2 0.3 Time_Days (h)


Bis(2-chloroethoxy)methane-rat-HTPBTK-ADmet, RMSLE=1.22 10 factor(Dose) Concentration (mg/L) 20 40 factor(Route) 10⁻¹ -10⁻² 0.1 0.2 0.3 0.4 0.0 Time_Days (h)






 $Bis (2-chloroethoxy) methane-rat-HTPBTK-Consensus,\ RMSLE=0.385$ 10 factor(Dose) Concentration (mg/L) 20 40 factor(Route) 10⁻¹ -10⁻² -0.2 0.3 0.4 0.0 0.1 Time_Days (h)





Isoeugenol-rat-HTPBTK-Dawson, RMSLE=1.73 10 factor(Dose) Concentration (mg/L) 17 70 140 factor(Route) oral 10⁻¹ -10⁻² 0.0 0.1 0.2 0.3 0.4 Time_Days (h)





Isoeugenol-rat-HTPBTK-OPERA, RMSLE=1.13 10 factor(Dose) Concentration (mg/L) 17 70 140 factor(Route) oral 10⁻¹ -0.1 0.2 Time_Days (h) 0.3 0.0 0.4


Isoeugenol-rat-HTPBTK-Consensus, RMSLE=1.18 10 factor(Dose) Concentration (mg/L) 17 70 140 factor(Route) oral 10⁻¹ -0.2 Time_Days (h) 0.1 0.3 0.0 0.4


Isoeugenol-rat-In Vivo Fits, RMSLE=0.54 10 factor(Dose) Concentration (mg/L) 17 70 140 factor(Route) oral 10⁻¹ -10⁻² 0.0 0.1 0.2 0.3 0.4 Time_Days (h)

Emodin-rat-HTPBTK-ADmet, RMSLE=1.81 10² factor(Dose) 10 -Concentration (mg/L) 5 40 80 factor(Route) · oral 1 -10⁻¹ 0.2 0.1 0.3 0.4 0.5 0.0 Time_Days (h)














Emodin-rat-In Vivo Fits, RMSLE=0.225 10factor(Dose) Concentration (mg/L) 5 40 80 1 factor(Route) · oral 10⁻¹ -0.2 0.1 0.4 0.5 0.0 0.3 Time_Days (h)















Anthraquinone-rat-HTPBTK-ADmet, RMSLE=1.78 10² -10 factor(Dose) 2 Concentration (mg/L) 40 100 400 factor(Route) oral 10⁻¹ -0.25 0.50 0.00 0.75 1.00 Time_Days (h)







Anthraquinone-rat-HTPBTK-Consensus, RMSLE=1.4 10² -10factor(Dose) 2 Concentration (mg/L) 40 100 400 factor(Route) · oral 10⁻¹ -0.25 0.50 0.75 0.00 1.00 Time_Days (h)














Oxymetholone-rat-HTPBTK-OPERA, RMSLE=1.09 30 -10factor(Dose) Concentration (mg/L) 20 30 3 -120 factor(Route) oral 1 -0.3 -0.2 0.0 0.1 0.4 0.5 0.3 Time_Days (h)
















































Diclofenac-rat-HTPBTK-Consensus, RMSLE=0.484 10² -30 factor(Dose) Concentration (mg/L) 18 60 factor(Route) 10 iv · oral 3 -0.1 0.0 0.2 0.3 Time_Days (h)














Diltiazem-rat-In Vivo Fits, RMSLE=0.214 10 -1 -Concentration (mg/L) factor(Route) · oral factor(Dose) 20 10⁻¹ 0.0 0.1 0.2 0.4 0.3 Time_Days (h)
































Thiodiglycolic acid-rat-HTPBTK-Consensus, RMSLE=0.487 30 -10-Concentration (mg/L) factor(Dose) 20 3 factor(Route) iv 1 -0.3 -0.0 0.1 0.2 0.3 0.4 Time_Days (h)




Oxoacetic acid--water (1/1)-rat-HTPBTK-OPERA, RMSLE=0.711 10² -30 -Concentration (mg/L) factor(Dose) 50 factor(Route) iv 10 -3 -0.005 0.010 0.015 0.020 Time_Days (h)


Oxoacetic acid--water (1/1)-rat-HTPBTK-Consensus, RMSLE=0.711 10² -30 -Concentration (mg/L) factor(Dose) 50 factor(Route) iv 10 -3 -0.010 0.005 0.015 0.020 Time_Days (h)








2-Methyltetrahydrofuran-rat-HTPBTK-Consensus, RMSLE=0.668 10² factor(Dose) 10 -2.5 10 Concentration (mg/L) 30 40 100 400 factor(Route) oral 10⁻¹ -10⁻² -0.2 0.0 0.1 0.3 0.4 0.5 Time_Days (h)















3,3',4,4',5-Pentachlorobiphenyl-rat-HTPBTK-OPERA, RMSLE=5.61 10² -1 -Concentration (mg/L) factor(Route) oral factor(Dose) 10 1000 100 200 300 Ö Time_Days (h)


 $3, 3', 4, 4', 5-Pentachlorobiphenyl-rat-HTPBTK-Consensus,\ RMSLE=3.44$ 10² -1 factor(Route) Concentration (mg/L) oral factor(Dose) 10⁻² -10 1000 10⁻⁴ -0 100 300 200


Time_Days (h)




Potassium perfluorohexanesulfonate-rat-In Vivo Fits, RMSLE=0.807 10² factor(Dose) 10 -Concentration (mg/L) 16 32 factor(Route) oral 10⁻¹ -20 0 10 40 30 50 Time_Days (h)


Potassium perfluorobutanesulfonate-rat-In Vivo Fits, RMSLE=0.55 10² factor(Dose) 10-Concentration (mg/L) 20 100 factor(Route) · oral 10⁻¹ -0.5 1.0 1.5 0.0 2.0 Time_Days (h)






Perfluorooctanesulfonate-rat-In Vivo Fits, RMSLE=0.452 10² -10 factor(Route) Concentration (mg/L) · oral factor(Dose) 1 -2 20 10⁻¹ -0 50 100 Time_Days (h)







Hexachlorobenzene-rat-In Vivo Fits, RMSLE=0.403 10-1 factor(Route) Concentration (mg/L) · oral factor(Dose) 10⁻¹ 0.03 0.1 0.3 30 10⁻² -10⁻³ -40 60 0 20 80 Time_Days (h)